Free Trial
OTCMKTS:CNBX

CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

$0.0080
+0.00 (+23.08%)
(As of 06/21/2024 09:00 PM ET)
Today's Range
$0.0074
$0.0090
50-Day Range
$0.0065
$0.0148
52-Week Range
$0.01
$0.05
Volume
315,500 shs
Average Volume
269,681 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CNBX stock logo

About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.

CNBX Stock Price History

CNBX Stock News Headlines

CNBX Pharmaceuticals Inc CNBX
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
CNBX Historical Data
CNBX - CNBX Pharmaceuticals Inc.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
CNBX Pharmaceuticals Inc
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBXD)
CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Granted Patent in Hong Kong
See More Headlines
Receive CNBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Cannabis
Current Symbol
OTCMKTS:CNBX
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Gabriel Yariv (Age 48)
    President, COO & Executive Chairman
    Comp: $241.67k
  • Mr. Uri Ben-Or CPA (Age 54)
    CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $40.32k
  • Mr. Eyal Barad (Age 59)
    Co-Founder, CEO & Director
    Comp: $269.15k
  • Dr. Sanja Goldberg (Age 48)
    Chief Technology Officer
    Comp: $48.12k
  • Noam Permont
    Vice President of Public Relations & Investor Relations
  • Dr. Sigalit Ariely-Portnoy Ph.D. (Age 60)
    Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board
  • Dr. Tal Mofkadi Ph.D.
    Financial Advisor & Member of Advisory Board
  • Mr. Yasha Borstein (Age 61)
    Chief Data Officer
  • Dr. Yaakov Waksman (Age 72)
    Head of Cannabidiol Research
  • Dr. Ilya Reznik M.D.
    Head of Neuropsychiatry Development

CNBX Stock Analysis - Frequently Asked Questions

How have CNBX shares performed in 2024?

CNBX Pharmaceuticals' stock was trading at $0.0142 at the beginning of 2024. Since then, CNBX stock has decreased by 43.7% and is now trading at $0.0080.
View the best growth stocks for 2024 here
.

When did CNBX Pharmaceuticals' stock split?

CNBX Pharmaceuticals shares reverse split on the morning of Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA).

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CNBX) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners